Hospira says 2013 guidance assumes inspections progress well Hospira said in conference call presentation slides that its 2013 outlook assumes FDA manufacturing facility inspections progress well, particularly at Rocky Mount. Hospira guided its 2013 gross margin at 35%-37% and operating margin at 11%-13%.
News For HSP From The Last 14 Days
Check below for free stories on HSP the last two weeks.
Cubist options active on speculation of a favorable patent ruling Cubist (CBST) June 55 calls and June 47 puts are active on total call volume of 3K contracts (3K puts). June call option implied volatility is at 37, August is at 40; compared to its 26-week average of 36 according to Track Data. Active option volume suggests traders taking positions for movement on speculation of a favorable patent ruling vs.Hospira (HSP).
Hospira reappoints Dr. Sumant Ramachandra to Chief Scientific Officer Ramachandra has been reappointed to his role as Senior VP and Chief Scientific Officer effective May 17. Ramachandra returns to Hospira after a brief departure earlier this year.